Wuxi Biologics (Cayman) Inc. (HK:2269)
:2269
Want to see HK:2269 full AI Analyst Report?
Top Page
Wuxi Biologics (Cayman)
(2269)
Select Model
Select Model
Rating:64Neutral
Price Target:
HK$35.00
▼(-2.02% Downside)
Action:Reiterated
Date:05/03/26
The score is driven primarily by solid fundamentals—healthy profitability and a low-leverage balance sheet—tempered by slowing revenue growth and weaker cash conversion. Technical signals are a meaningful drag due to a bearish trend (below major moving averages with negative MACD), while valuation is moderately supportive with a low P/E.
Positive Factors
Strong profitability and margins
Sustained high gross and operating margins indicate durable operational strength and pricing power across biologics services. Higher margins support reinvestment in capacity and R&D, provide cushion against pricing pressure, and underpin long-term free cash generation potential.
Negative Factors
Slowing revenue growth
A marked deceleration in top-line growth reduces the pace at which scale economies and fixed-cost absorption can improve returns. If the slowdown persists, capacity utilization, pricing leverage and long-term revenue visibility could be constrained, weakening future margin expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong profitability and margins
Sustained high gross and operating margins indicate durable operational strength and pricing power across biologics services. Higher margins support reinvestment in capacity and R&D, provide cushion against pricing pressure, and underpin long-term free cash generation potential.
Read all positive factors
Wuxi Biologics (Cayman) (2269) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$137.23B
Dividend YieldN/A
Average Volume (3M)32.67M
Price to Earnings (P/E)24.3
Beta (1Y)1.83
Revenue Growth16.79%
EPS Growth47.14%
CountryHK
Employees12,575
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.19
Shares Outstanding4,140,823,700
10 Day Avg. Volume33,789,006
30 Day Avg. Volume32,668,415
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)2.53
Price to Sales (P/S)5.48
P/FCF Ratio42.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$45.32Price Target Upside26.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)1.33
Revenue Forecast (FY)HK$25.24B
Wuxi Biologics (Cayman) Business Overview & Revenue Model
Company Description
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision...
How the Company Makes Money
Wuxi Biologics makes money primarily by providing fee-based outsourced services to biopharmaceutical customers across the biologics lifecycle. Its key revenue streams typically include: (1) discovery and preclinical services—project-based fees for...
Wuxi Biologics (Cayman) Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
67
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 21.79B | 18.68B | 17.03B | 15.27B | 10.29B |
| Gross Profit | 10.02B | 7.65B | 6.83B | 6.72B | 4.83B |
| EBITDA | 7.92B | 6.43B | 5.50B | 6.22B | 4.51B |
| Net Income | 4.91B | 3.36B | 3.40B | 4.42B | 3.39B |
Balance Sheet | |||||
| Total Assets | 63.72B | 56.98B | 56.58B | 49.56B | 44.03B |
| Cash, Cash Equivalents and Short-Term Investments | 15.74B | 10.71B | 11.24B | 8.71B | 11.13B |
| Total Debt | 3.11B | 4.94B | 4.56B | 4.42B | 4.30B |
| Total Liabilities | 10.66B | 11.50B | 12.56B | 13.35B | 11.33B |
| Stockholders Equity | 47.27B | 41.82B | 40.33B | 35.05B | 32.28B |
Cash Flow | |||||
| Free Cash Flow | 2.80B | 1.29B | 437.20M | -326.72M | -3.09B |
| Operating Cash Flow | 6.39B | 5.22B | 4.67B | 5.54B | 3.43B |
| Investing Cash Flow | -3.38B | -3.94B | -3.23B | -5.91B | -9.60B |
| Financing Cash Flow | -1.95B | -2.75B | 1.96B | -2.59B | 8.21B |
Wuxi Biologics (Cayman) Technical Analysis
Negative
35.72
Price Trends
34.34
Negative
35.78
Negative
35.19
Negative
Market Momentum
-0.49
Positive
44.81
Neutral
44.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2269, the sentiment is Negative. The current price of 35.72 is above the 20-day moving average (MA) of 33.60, above the 50-day MA of 34.34, and above the 200-day MA of 35.19, indicating a bearish trend. The MACD of -0.49 indicates Positive momentum. The RSI at 44.81 is Neutral, neither overbought nor oversold. The STOCH value of 44.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2269.
Wuxi Biologics (Cayman) Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$51.05B | 22.45 | 11.22% | 1.04% | 16.83% | -8.65% | |
64 Neutral | HK$137.23B | 24.33 | 10.55% | ― | 16.79% | 47.14% | |
62 Neutral | HK$28.49B | -6.49 | -12.75% | ― | ― | ― | |
58 Neutral | HK$20.67B | 25.33 | 11.29% | ― | 48.38% | ― | |
53 Neutral | HK$3.07B | 17.96 | 5.53% | ― | -12.90% | 33.65% | |
52 Neutral | HK$1.94B | 38.94 | 1.98% | ― | 0.61% | 766.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:2269
Wuxi Biologics (Cayman)
33.14
8.44
34.17%
HK:1548
Genscript Biotech
13.09
2.15
19.65%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
18.28
4.86
36.19%
HK:1521
Frontage Holdings Corp.
0.95
-0.18
-15.93%
HK:1873
Viva Biotech Holdings
1.45
-0.28
-16.18%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
50.60
36.32
254.34%
Wuxi Biologics (Cayman) Corporate Events
Wuxi Biologics Grants 25.6 Million Restricted Shares Under Incentive Scheme
Mar 25, 2026
Wuxi Biologics has approved the grant of 25,575,356 restricted shares at no purchase price to 1,946 grantees, including directors, an associate of a director, and employees, under its Restricted Share Award Scheme. The shares, valued at HK$33.14 e...
WuXi Biologics Schedules Briefings on 2025 Annual Results for Global Investors
Mar 24, 2026
WuXi Biologics (Cayman) Inc., a Hong Kong-listed biologics contract development and manufacturing organization, serves global pharmaceutical and biotechnology companies with end-to-end services. The company plays a key role in enabling partners to...
Wuxi Biologics Delivers Strong 2025 Profit Growth as Project Portfolio Expands
Mar 24, 2026
Wuxi Biologics reported strong 2025 results, with revenue rising 16.7% to RMB 21.79 billion and net profit jumping 45.3% to RMB 5.73 billion, driven by higher gross margins and robust earnings per share growth, though the board opted against a fin...
WuXi Biologics Forecasts Strong 2025 Profit Growth on Expanded Services and Efficiency Gains
Feb 10, 2026
WuXi Biologics (Cayman) Inc. has issued a positive profit alert, indicating that for the year ended December 31, 2025, revenue is expected to rise about 16.7% to RMB21.79 billion, with gross margin expanding by roughly five percentage points to 46...
WuXi Biologics Sets March 24 Board Meeting to Approve 2025 Annual Results
Feb 10, 2026
WuXi Biologics (Cayman) Inc. has scheduled a board meeting for March 24, 2026 to review and approve the group’s annual results for the financial year ended December 31, 2025. The approval and subsequent publication of these results will prov...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.